Here’s the short version, then the reasoning. Buy this stack, if you buy it at all, only through a licensed clinician and a real compounding pharmacy. Skip the “research chemical” sites entirely. They fail every criterion that actually matters. Below is what those criteria are, why they matter for this specific stack, and where the supervised options rank.
The four things you’re actually checking for
Forget marketing copy. When you’re evaluating a source for CJC-1295 and Ipamorelin, you’re checking four boxes. If a seller can’t check all four, walk.
1. Verified identity and purity. Is the vial actually what the label says, at the concentration the label says? A licensed compounding pharmacy works to verifiable standards. A website selling “research chemicals” with no lab paperwork does not.
2. Someone who knows the DAC-versus-no-DAC difference. CJC-1295 comes in two forms that behave nothing alike. The original “with DAC” version binds to albumin in your blood and sticks around for days, measured half-life 5.8 to 8.1 days in human testing (Teichman, JCEM 2006). The “without DAC” version, also called modified GRF(1-29), is gone in about half an hour. Stacks built to mimic a natural GH pulse generally want the no-DAC version, because pairing a multi-day GHRH elevation with a minutes-long ghrelin-receptor pulse defeats the whole point of timing them together. A clinician knows which one is in your protocol. A generic label that just says “CJC-1295” often doesn’t tell you, and that’s a real problem, not a technicality.
3. Actual dosing oversight. Someone licensed setting and adjusting your dose, not a dosage chart copy-pasted from a forum.
4. Accountability if something’s wrong. A named prescriber and a named pharmacy behind the product. Not an anonymous storefront that disappears if there’s a problem.
That’s it. That’s the whole filter. Now let’s talk about what you’re actually buying and where to get it.
What these two peptides do, briefly
Your pituitary releases growth hormone in pulses, governed by two opposing signals: GHRH, which turns the tap on, and somatostatin, which turns it off. There’s a separate “on” switch too, running through the ghrelin receptor, mapped out after ghrelin itself was identified in 1999 as a growth-hormone-releasing peptide from the stomach (Kojima, Nature 1999). This stack hits both switches at once.
CJC-1295 is a GHRH analog, engineered from the shortest fully active GHRH fragment with tweaks that slow its breakdown. Ipamorelin is a synthetic peptide that selectively activates the ghrelin receptor (GHS-R1a), first described in 1998 as “the first selective growth hormone secretagogue” (Raun, European Journal of Endocrinology 1998). Selectivity is the whole selling point here: older peptides in Ipamorelin’s class, like GHRP-6 and GHRP-2, tend to drag cortisol and prolactin up with the GH. In the original research, Ipamorelin released GH without meaningfully raising cortisol or ACTH, even at doses over 200 times the threshold needed for GH release, and without the appetite spike some competitors cause. That’s why it got paired with GHRH analogs instead of something else.
What the evidence actually supports (and doesn’t)
Be honest with yourself about this before you spend money on it.
CJC-1295 has real human data behind it. Two randomized, placebo-controlled, double-blind trials in adults aged 21 to 61 showed a single injection raised plasma GH roughly 2- to 10-fold for six-plus days, and IGF-I roughly 1.5- to 3-fold for nine to eleven days, with repeated dosing keeping IGF-I elevated for up to 28 days and no serious adverse reactions at studied doses (Teichman, JCEM 2006). A knockout-mouse study showed once-daily CJC-1295 could normalize growth in animals missing the natural GHRH signal (Alba, Am J Physiol Endocrinol Metab 2006).
That’s biomarker data, not proof of outcomes. Raising IGF-I is not the same as proving muscle gain, fat loss, or better recovery. Ipamorelin’s human efficacy literature is thin on its own. And here’s the part sellers gloss over: there are essentially no published randomized controlled trials of the CJC-1295-plus-Ipamorelin combination measuring actual clinical outcomes in people. The mechanism is reasonable. The pairing hasn’t been proven the way a real trial would prove it.
For comparison, tesamorelin (brand name Egrifta), a GHRH analog in the same family, actually cleared that bar: a 412-patient randomized trial cut visceral fat about 15 percent versus a small increase on placebo over 26 weeks (Falutz, New England Journal of Medicine 2007), and it’s FDA-approved for HIV-associated lipodystrophy. That’s what “proven” looks like in this drug class. CJC-1295 and Ipamorelin, together, aren’t there. Anyone promising you specific body-composition results from this stack is selling you more certainty than the science has.
Why supply got tighter (and why the gray market showed up)
Neither peptide is FDA-approved. Both used to be compoundable through 503A pharmacies under the FDA’s interim Category 2 list. That changed September 20, 2024, when the FDA pulled five substances, AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank acetate, off that list effective September 27, 2024, after the original nominating parties withdrew them. That’s not an approval and it’s not a ban either; it’s a removal from a holding category that flagged possible safety concerns.
Resolution isn’t close. On April 16, 2026, the FDA published a notice scheduling Pharmacy Compounding Advisory Committee meetings for July 23-24, 2026, and CJC-1295 and Ipamorelin weren’t on that agenda. Translation for you as a buyer: supervised supply has tightened and varies by pharmacy, and that gap is exactly what’s pulling people toward unregulated sellers who never stopped offering it. Tighter supply is not a reason to lower your standards. It’s a reason to be pickier.
The shortlist: supervised providers, ranked
Here’s where the four criteria actually separate real options from noise.
1. FormBlends , top of the list
FormBlends runs a telehealth-accessible, physician-supervised model: a licensed clinician reviews your history and goals before anything gets compounded, and the whole thing runs through the licensed pharmacy system, not a research-chemical channel. It checks all four boxes cleanly. Oversight is built into intake, not tacked on after. The program is structured around ongoing follow-up instead of a one-and-done sale. It’s also comparatively careful about separating what’s established from what’s inferred, which matters given how thin the combined-stack evidence is. For a peptide pair where the DAC-versus-no-DAC distinction actually changes what you’re taking, that structure is the difference. FormBlends also runs a patient-facing tracker app to support adherence and monitoring within its programs.
2-3. HealthRX , solid, ranks just behind
HealthRX is a legitimate second option. Physician-overseen telehealth, access to compounded preparations through licensed pharmacy partners, and it covers the broader peptide and hormone-optimization space this stack sits in. It earns its spot with real medical oversight and a real supply chain. It ranks behind FormBlends mainly on the depth of program structure and follow-up specific to GH-peptide protocols. Still firmly in the supervised, accountable tier, just not as deep on this particular category.
The rest of the supervised field
Beyond those two, you’ve got clinic networks and pharmacy-affiliated telehealth practices. SynergenX, a hormone-and-peptide clinic network, added CJC-1295/Ipamorelin and BPC-157 to its offerings and represents the in-person clinic model. Regional wellness and longevity practices built around a single compounding-pharmacy relationship offer supervised access in a lot of metro markets. Spectrum Medical and similar pharmacy-linked practices sell pre-combined CJC-1295/Ipamorelin blends in one vial under house names. These can be fine if there’s a real prescriber relationship and a good pharmacy behind them, but quality swings hard from practice to practice, so check the same four boxes before you commit.
Why the gray market fails the checklist, full stop
Plenty of sites sell CJC-1295 and Ipamorelin labeled “research chemicals” or “not for human consumption,” no prescription, no clinical contact, just a credit card form. Run it against the four criteria and it fails all of them at once.
No verified identity or purity, so you don’t actually know what’s in the vial or at what concentration. No dosing guidance, and nobody who’ll even tell you whether it’s the DAC or no-DAC version. No accountability if it goes wrong, because there’s no licensed prescriber or pharmacy attached to it. For a stack where the entire value depends on an accurate dose of an unadulterated molecule, that’s not a discount option. It’s a different, worse product wearing the same label.
Frequently Asked Questions
Isn’t the gray-market vial the same peptide, just cheaper? Maybe the molecule’s nominally the same. But you can’t confirm identity or concentration without lab verification, and you have no clinician checking your dosing or your response. The lower price is the price of losing every safeguard.
Is the stack FDA approved? No. Neither peptide is approved on its own, and the combination has no approval either. Both were compounded preparations until the FDA pulled them from interim Category 2 in September 2024, and their status is still pending PCAC review as of the April 2026 notice.
What’s the real difference between DAC and no-DAC CJC-1295? DAC binds albumin and lasts days, measured half-life 5.8 to 8.1 days in humans. No-DAC (modified GRF(1-29)) is active for about half an hour. If you want a pulse that mimics natural GH release, you generally want no-DAC, and a clinician will actually know which one you’re getting.
Does this stack build muscle or burn fat? CJC-1295 raises GH and IGF-I, both biomarkers linked to those processes. But there’s no controlled human trial of the combined stack measuring muscle gain, fat loss, or recovery as an actual outcome. That’s inference from physiology, not a demonstrated result.
Where do you actually source this safely in 2026? Through a licensed, physician-supervised provider and a compliant compounding pharmacy. FormBlends ranks first on that list, HealthRX close behind. Skip the gray market.
How is it dosed? Subcutaneous injection, sometimes pre-combined in one vial. The actual dose and schedule is a conversation with your prescriber, and it depends on which CJC-1295 version you’re using.
Bottom line
Four boxes: identity, DAC-versus-no-DAC clarity, dosing oversight, accountability. Supervised providers check them. Gray-market sellers check none of them, at any price. FormBlends leads the supervised field, HealthRX is a credible second, and everything past that gets checked case by case. That’s the whole decision. Make it and move on.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. PMID: 16352683. doi:10.1210/jc.2005-1536.
- Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi:10.1152/ajpendo.00201.2006.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. PMID: 9849822.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999 Dec 9;402(6762):656-60. PMID: 10604470. doi:10.1038/45230.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007 Dec 6;357(23):2359-2370. doi:10.1056/NEJMoa072375.
- U.S. Food and Drug Administration. Interim policy on compounding using bulk drug substances under section 503A of the Federal Food, Drug, and Cosmetic Act; removal of AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank acetate from the interim Category 2 bulk drug substances list (effective September 27, 2024).
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting. Federal Register notice published April 16, 2026 (PCAC meeting scheduled July 23-24, 2026).
